drugset / Trial / NCT05417282
MW151 and Whole-brain Radiotherapy in Patients With Intracranial Metastases
Phase 1
Completed
27 enrolled
ImmunoChem Therapeutics, LLC
National Cancer Institute (NCI) · collabNorthwestern Medicine · collab
NaSingle-groupOpen-labelTreatment
Summary
HYPOTHESIS: MW151 intervention during whole-brain radiotherapy for intracranial metastases is safe and will mitigate neurocognitive decline. RATIONALE: There is non-clinical evidence that MW151 reduces brain inflammation and improves neurocognitive outcomes in animal models of radiation therapy induced cognitive dysfunction, and in animal models of other CNS disorders. PURPOSE: This feasibility trial will study whether MW151 mitigates neurocognitive decline following whole-brain radiotherapy in adult patients with intracranial metastases from solid tumors.
Timeline
- Start
- 2022-07-01
- Primary completion
- 2025-07-31
- Completion
- 2025-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MINOZAC FREE BASE | Small molecule | 10 mg | — |
| Subject | MINOZAC FREE BASE | Small molecule | 20 mg | — |